Vienna-based Nabriva Therapeutics has rounded up $22 million in new venture backing for its work on developing a new class of antibiotics for serious infections caused by resistant pathogens. Nomura Phase 4 Ventures, HBM Partners, Wellcome Trust, GLS Ventures, and Novartis Venture Fund participated in this round, which brings its total VC take to $84 million in three years.
"These additional funds extend Nabriva's cash reach into 2011 and will fund the development of our systemic pleuromutilin program up to and including the generation of Phase II efficacy data in the second half of 2010," said Nabriva CEO Dr. David Chiswell.
- see Nabriva's release